Tonix Pharmaceuticals Holding Corp - Company Profile
Powered by 
All the sales intelligence you need on Tonix Pharmaceuticals Holding Corp in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Tonix Pharmaceuticals Holding Corp fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Tonix Pharmaceuticals Holding Corp.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Tonix Pharmaceuticals Holding Corp (Tonix) a developer of pharmaceutical products to address public health challenges. The company's pipeline products include TNX-102 SL treats fibromyalgia, long covid, acute stress disorder; TNX-1500 is for the treatment of cocaine intoxication; TNX-1500 treats organ transplant rejection and autoimmune disorders; TNX-1700 for gastric and colorectal cancer; TNX-801 targets smallpox and monkeypox preventing vaccine; TNX-1850 treats Covid 19 vaccine; TNX-2900 is for the treatment of prader willi syndrome. Tonix also provide clinical trial services. It has operations in Ireland, Canada and the US. Tonix is headquartered in Berkeley Heights, New Jersey, the US.
Headquarters
United States of America
Address
200 Connell Drive, Suite 3100, Berkeley Heights, New Jersey, 07922
Website
www.tonixpharma.com
Telephone
1 862 7998599
No of Employees
142
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
TNXP (NASD)
Revenue (2024)
$13.1M
29.8%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
4.6%
(2024 vs 2023)
Market Cap*
$233.9M
Net Profit Margin (2024)
XYZ
26.6%
(2024 vs 2023)
* As of and is in US$
Tonix Pharmaceuticals Holding Corp premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Central Nervous System Portfolio: |
| TNX-102 SL: Fibromyalgia (FM) |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Tonix Pharmaceuticals Holding Corp | Alnylam Pharmaceuticals Inc | Sarepta Therapeutics Inc | Astria Therapeutics Inc | Azevan Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Berkeley Heights | Cambridge | Cambridge | Boston | Bethlehem |
| State/Province | New Jersey | Massachusetts | Massachusetts | Massachusetts | Pennsylvania |
| No. of Employees | 142 | 2,500 | 835 | 78 | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Seth Lederman, MD | Chief Executive Officer; Chief Medical Officer - Interim; Chairman | Executive Board | 2026 | 67 |
| Bradley Saenger | Chief Financial Officer | Senior Management | 2016 | 51 |
| Jessica Edgar Morris | Chief Operating Officer | Senior Management | 2018 | 47 |
| Zeil Rosenberg | Executive Vice President - Medical | Senior Management | 2023 | - |
| Irina Ishak | General Counsel | Senior Management | 2025 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer